Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function - PubMed
5 hours ago
- #Ticagrelor
- #Multidrug Resistance
- #Breast Cancer
- Ticagrelor reverses multidrug resistance (MDR) in breast cancer by inhibiting the PI3K/AKT/mTOR pathway.
- It suppresses ABCB1 expression and function, enhancing the cytotoxicity of chemotherapeutic agents like Adriamycin and Paclitaxel.
- Ticagrelor combined with Adriamycin downregulates PI3K/mTORC1 and PI3K/mTORC2 signaling pathways and reduces EMT-related protein levels.
- In xenograft models, Ticagrelor and Adriamycin combination significantly suppresses tumor growth compared to monotherapy.
- The study highlights Ticagrelor's potential as a dual-acting agent targeting both tumor metastasis and chemoresistance.